Articles Referencing SNY
Sanofi/REGN Commence Enrollment - Analyst Blog
5/15/2013, 5:28 pm from Zacks.com in Investing, Business, Stocks
Sanofi ( SNY ) and partner
Regeneron Pharmaceuticals, Inc. ( REGN ) recently
announced that they started enrolling patients for two phase III
trials (SARIL-RA COMPARE and SARIL-RA... Read >>
FDA Accepts Merck BLA - Analyst Blog
5/15/2013, 12:30 pm from Zacks.com in Investing, Business, Stocks
Merck ( MRK ) recently
announced that the US Food and Drug Administration (FDA) has
accepted its Biologics License Application (BLA) for its ragweed
pollen (ambrosia artemisiifolia)... Read >>
LabStyle Innovations - Glucose Monitoring For The Mobile Age
5/15/2013, 12:24 pm from SeekingAlpha in Investing, Technology
By Jason
Napodano : Today, Zacks initiated coverage of LabStyle Innovations Corp.
(DRIO.OB) with a Buy rating. LabStyle is a healthcare technology
company that has developed an... Read >>
Isis Reports In-Line Loss - Analyst Blog
5/8/2013, 6:25 pm from Zacks.com in Investing, Business, Stocks
Isis Pharmaceuticals Inc. ( ISIS ) reported a net
loss of 3 cents per share in the first quarter of 2013, in line
with the Zacks Consensus Estimate. The loss was narrower than the
year-ago... Read >>
Osiris Loss In-Line with Expectations - Analyst Blog
5/8/2013, 6:24 pm from Zacks.com in Investing, Business, Stocks
Osiris Loss In-Line with Expectations Osiris Therapeutics Inc. ( OSIR ) reported a
first-quarter 2013 loss of 8 cents per share, in-line with the
Zacks Consensus Estimate but wider than... Read >>
MYGN Earnings Easily Beat, Guidance Up - Analyst Blog
5/8/2013, 5:25 pm from Zacks.com in Investing, Business, Earnings, Stocks
Myriad Genetics Inc. ( MYGN ) reported
earnings per share (EPS) of 46 cents in the third quarter of fiscal
2013, representing a beat of 17.9% over the Zacks Consensus
Estimate and EPS... Read >>
Merck's Liptruzet Approved in the US - Analyst Blog
5/7/2013, 12:22 pm from Zacks.com in Investing, Business, Stocks
Merck ( MRK ) recently gained
US Food and Drug Administration (FDA) approval for its combination
cholesterol treatment, Liptruzet. The FDA granted approval to
Liptruzet for the treatment of... Read >>
Good News for Bristol-Myers - Analyst Blog
5/6/2013, 4:23 pm from Zacks.com in Investing, Business, Stocks
Bristol-Myers Squibb Company ( BMY ) recently received
positive news from the US Food and Drug Administration (FDA) when
the US regulatory authority approved the pharma major's HIV... Read >>
Teva Beats on Earnings, Revenues - Analyst Blog
5/6/2013, 1:02 pm from Zacks.com in Investing, Business, Earnings, Stocks
Teva Pharmaceutical Industries ( TEVA ) reported first
quarter earnings of $1.12 per American Depositary Share (ADS), a
couple of cents above the Zacks Consensus Estimate but 23.8%... Read >>
Netupitant Results Could Roil Tesaro In May
5/6/2013, 9:25 am from SeekingAlpha in Investing, Stocks
By Richard
Pearson : Shares of Tesaro Inc. ( TSRO ) have recently
traded to new all-time highs and are now sitting at $29.40. The
shares have now more than doubled since coming public at... Read >>
Eylea Drives Earnings at Regeneron - Analyst Blog
5/3/2013, 2:35 pm from Zacks.com in Investing, Business, Earnings, Stocks
Regeneron Pharmaceuticals Inc .'s ( REGN ) first quarter
2013 earnings (excluding special items but including stock-based
compensation) of $1.30 per share breezed past the Zacks... Read >>
Earnings Plummet, Outlook Maintained at Sanofi - Analyst Blog
5/3/2013, 1:30 pm from Zacks.com in Investing, Business, Earnings, Stocks
Sanofi ( SNY ) reported first
quarter 2013 business earnings of 81 cents per American Depository
Share (ADS), below the Zacks Consensus Estimate of 89 cents.
Earnings were down 29.0% at... Read >>
Sanofi (SNY) Ex-Dividend Date Scheduled for May 06, 2013
5/3/2013, 9:00 am from NASDAQ.com News in News Headlines, Stocks
Sanofi ( SNY )
will begin trading ex-dividend on May 06, 2013. A cash dividend
payment of $1.8624 per share Shareholders who purchased SNY stock
prior to the ex-dividend date are eligible for... Read >>
Are These The Biotech Stars Of Tomorrow?
5/2/2013, 11:00 am from StreetAuthority in Investing, Investing Ideas, Stocks
In the past 30 years, hundreds of thousands of people have been
given a second chance after battling cancer. Many of these cancer
survivors have long been in remission, but there's still reason... Read >>
Loss Widens at Momenta - Analyst Blog
5/2/2013, 9:57 am from Zacks.com in Investing, Business, Stocks
Momenta Pharmaceuticals Inc. ( MNTA ) reported first
quarter 2013 net loss per share of 48 cents, wider than the Zacks
Consensus Estimate of a loss of 43 cents and the year-ago loss of
10... Read >>